文献速递乳腺癌放疗

肿瘤床加量与否的局部复发:DBCG IMN2 研究的事后分析

Local recurrence with and without a tumour-bed boost: A post-hoc analysis of the DBCG IMN2 study.
PubMed 文献 · Radiother Oncol · 2025-05-04

该事后分析纳入 DBCG IMN2 研究中 2,430 例接受保乳手术的淋巴结阳性乳腺癌患者,中位随访 13.7 年,5 年局部复发累积发生率为 1.7%,10 年为 3.6%。在 ≥50 岁未接受肿瘤床加量的 1,872 例患者中,仅 ER-/HER2- 亚组 10 年局部复发率达 8.3%,提示该亚组可能从肿瘤床加量中获益。

要点

  • 淋巴结阳性保乳术后患者 10 年局部复发累积发生率为 3.6%。
  • ≥50 岁未加量患者中仅 ER-/HER2- 亚组 10 年局部复发率超 6%。
  • ≥50 岁 ER-/HER2- 淋巴结阳性患者或可从肿瘤床加量中获益。

核心结论

  • ≥50 岁、ER-/HER2- 的淋巴结阳性保乳术后患者可能从肿瘤床加量中获得临床相关获益。

研究设计与样本

  • DBCG IMN2 研究的事后分析,纳入 2,430 例淋巴结阳性、接受保乳手术的患者。
  • 患者接受全乳及区域淋巴结 3D 适形放疗,按侧别决定是否行内乳淋巴结照射。
  • 肿瘤床加量序贯给予:41-49 岁为 10 Gy/5 次,≤40 岁或切缘<2 mm 为 16 Gy/8 次。
  • 有和无肿瘤床加量的患者分开分析,预设亚组包括已知预后危险因素。

主要发现

  • 中位随访 13.7 年,局部复发累积发生率 5 年为 1.7%(95%CI 1.2-2.2),10 年为 3.6%(95%CI 2.9-4.3)。
  • ≥50 岁未接受肿瘤床加量的 1,872 例患者中,145 例 ER-/HER2- 肿瘤患者 10 年局部复发累积发生率为 8.3%(95%CI 4.5-13.5)。
  • 除 ER-/HER2- 亚组外,其他亚组 10 年局部复发率均未超过 6%。

关键数值与推荐

  • 原文提及 5 年 3% 和 10 年 6% 的局部复发率被提议作为肿瘤床加量获益大于潜在不良影响的阈值。
  • ≥50 岁未加量患者中,ER-/HER2- 亚组 10 年局部复发率为 8.3%(95%CI 4.5-13.5),超过 6% 阈值。
  • 其他预设亚组 10 年局部复发率均未超过 6%。

临床怎么用

  • 对于 ≥50 岁、淋巴结阳性、ER-/HER2- 的保乳术后乳腺癌患者,可考虑给予肿瘤床加量以降低局部复发风险。
  • 其他亚组是否加量需结合个体风险权衡,因多数亚组 10 年局部复发率未超过 6%。

局限性

  • 本文为事后分析,非随机比较肿瘤床加量与否。
  • 有和无肿瘤床加量的患者分开分析,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: In early-stage breast cancer, a tumour-bed boost (TBB) reduces the risk of local recurrence (LR) by around 50 % but increases the risk of breast induration. LR incidences of 3 % at 5 years and 6 % at 10 years have been proposed as thresholds where benefits outweigh the potentially detrimental effects of a TBB. Therefore, this post-hoc analysis of the Danish Breast Cancer Group (DBCG) IMN2 study aimed to investigate LR rates according to prognostic risk factors to identify indications for a TBB. MATERIAL AND METHODS: From the DBCG IMN2 study, 2,430 node-positive patients operated with breast-conserving surgery were included for analysis. They received irradiation to the residual breast and regional nodes with or without internal mammary node irradiation according to laterality. Radiotherapy was 3D-conformal. TBB was delivered sequentially as 10 Gy/5 Fx (41-49 years) and 16 Gy/8 Fx (≤ 40 years or margin < 2 mm). Patients with and without a TBB were analysed separately. Prespecified subgroups included known prognostic risk factors. RESULTS: Median follow-up was 13.7 years, and the cumulative incidence of LR was 1.7 % (95 % CI, 1.2-2.2) at 5 years and 3.6 % (95 % CI, 2.9-4.3) at 10 years. In patients ≥ 50 years, 1,872 patients were treated without a TBB. Among these, 145 patients with an ER-/HER2- tumour had a 10-year cumulative incidence of LR of 8.3 % (95 % CI, 4.5-13.5). No other subgroups exceeded 6 % at 10 years. CONCLUSION: Our results suggest that node-positive patients 50 years or older with an ER-/HER2- tumour may obtain a clinically relevant benefit from a TBB.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Nielsen AWM, Thorsen LBJ, Özcan D, et al. Local recurrence with and without a tumour-bed boost: A post-hoc analysis of the DBCG IMN2 study. Radiother Oncol. 2025. PMID: 40324911. doi:10.1016/j.radonc.2025.110905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。